cancer-therapy-and-biomarkers-2016_tracks-abstracts

11 / 36

Volume 2, Issue 3(Suppl) Oncol Cancer Case Rep
ISSN: 2471-8556 an open access journal
Page 33
Notes:
Cancer Therapy & Biomarkers 2016
December 05-07, 2016
conferenceseries.com
CANCER THERAPY,
BIOMARKERS & CLINICAL RESEARCH
15th World Congress on
December 05-07, 2016 Philadelphia, USA
Serum fatty acid synthase as a marker of digestive neoplasia
Hajime Orita
Shizuoka Hospital-Juntendo University, Japan
The aim of this study is to evaluate FAS as a marker of digestive cancer to measure FAS serum levels in patients with digestive
cancer and explore each digestive cancer metabolic features. Cancer metabolism is a futuristic strategy point for diagnosis
and management. Lipid metabolism in particular is a vast uncharted territory for targeting tumor control. It is well known
that many cancer cells up-regulate of fatty acid synthesis. Cancer cells require fatty acid for building blocks of new organelles
and cells. Fatty Acid Synthase (FAS) is the enzyme responsible for fatty acid biosynthesis. It is over-expressed in many human
cancers, reported to be correlated with cancer growth, contributes to poor prognosis and inhibition of FAS results in decreased
cell proliferation, and loss of cell viability. Previously we have reported high expression not only in tissue, but also in serum in
patients with digestive cancers. Although FAS is found to be over-expressed in many solid tumors, its role in digestive cancer
has not been extensively evaluated. We have reported that it seems to be up-regulated during the early stages of tumorigenesis.
In Digestive neoplasm, Upper GI (esophageal and gastric) and colorectal ones have different characteristics due to carcino-
genesis. Upper GI neoplasm results from the continuous inflammation from Helicobacter pylori and various other factors.
Therefore colorectal one arises from adenoma carcinoma sequences. Our results show a different tendency for each other.
Compare between premalignant status and malignancy, by using serum and tumor FAS level we can approach the mechanism
of reprogramming the regulation of metabolic pathways.
Biography
Hajime Orita graduated and took the surgical training from Juntendo University School of medicine in Japan. Now he is the associate professor of dept. of upper GI
and especially do laparoscopic surgery. He had been post doctal studies and recived the adjunct associate professor degrer from Johns Hopkins University School
of medicine. He has published more than 10 papers in reputed journals and has been serving as an editorial board member of repute.
Hajime Orita, Oncol Cancer Case Rep 2016,2:3(Suppl)